Roche Spark Merger Agreement

Headquartered in Basel, Switzerland, the Roche Group operates in more than 100 countries and employed approximately 94,000 people worldwide in 2018. In 2018, Roche invested chf 11 billion in research and development and generated sales of CHF 56.8 billion. Genentech in the United States is a 100% member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan. For more information, see www.roche.com. According to a press release, Roche and Spark Therapeutics, Inc. have entered into a definitive merger agreement. Roche pays $US 114.50 per share, representing a transaction value of approximately $4.3 billion. The merger agreement was unanimously approved by the boards of Directors of Spark Therapeutics and Roche. Roche will also try to acquire all outstanding shares of Spark Therapeutics.

IMPORTANT ADDITIONAL INFORMATION AND WHERE THERE IS THE TENDER OFFER FOR THE OUTSTANDING COMMON STOCK OF SPARK THERAPEUTICS HAS NOT STARTEDD. THIS AD IS ONLY FOR INFORMATION PURPOSES AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR SOLICITATION OF AN OFFER TO SELL SPARK THERAPEUTICS COMMON STOCK. THE SOLICITATION AND OFFER TO BUY SPARK THERAPEUTICS COMMON STOCK WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS. IN TIME THE OFFER IS COMMENCED, ROCHE AND ITS ACQUISITION SUBSIDIARY FILE A TENDER OFFER STATEMENT ON SCHEDULE TO WITH THE SEC AND THEREAFTER, SPARK THERAPEUTICS WILL FILE A SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH RESPECT TO THE OFFER. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) CAREFULLY WHEN THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. OFFER ON PURCHASE, SOLICITATION/RECOMMENDATION STATEMENT AND RELATED MATERIALS WILL BE FILED WITH THE SEC, AND INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THESE MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED BY ROCHE AND SPARK THERAPEUTICS WITH THE SEC AT THE WEBSITE AT WWW.SEC.GOV. INVESTORS AND SECURITY HOLDERS MAY www.sparktx.com Also About Spark Therapeutics At Spark Therapeutics, a fully integrated commercial company dedicated to the discovery, development and supply of gene therapies, we question the inevitability of genetic diseases, including blindness, hemophilia, lysosomal memory disorders and neurodegenerative diseases. We have successfully used our technology in the first gene therapy, approved in the United States and the EU for a genetic disease, and we currently have four clinical trial programs, including product candidates, that have shown promising early results in hemophilia patients. At Spark, we see the path to a world where life is not limited by genetic diseases.

For more information, visit www.sparktx.com and follow us on Twitter and LinkedIn. Terms of contract As part of the merger agreement, Roche will immediately launch a takeover bid for all outstanding common shares of Spark Therapeutics at a price of $114.50 per share in cash.

Comments are closed.